People · Operator
Named in public records as an officer, director or promoter · active 2010–2018 · Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Accele BioPharma, Inc. | — | Other Health Care | Seed | $2.6M | $64.5M | 2012 |
| Neuronex, Inc. | — | Pharmaceuticals | Pre-Seed | $1.2M | $18.9M | 2010 |
| Valanbio Therapeutics, Inc. | — | Pharmaceuticals | Pre-Seed | $421K | $19.9M | 2018 |
Clayton Duncan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Clayton Duncan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| MOISE KHAYRALLAH | 1 | 5 |
| STEPHEN BUTTS | 1 | 3 |
| GARY BREAM | 1 | 3 |
| Eric J. Toone | 1 | 1 |
| Sam Hopkins | 1 | 1 |
| Stephen Prescott | 1 | 1 |
| Carl Edwards | 1 | 1 |
| Pei J. Zhou | 1 | 1 |
| Moise A. Khayrallah | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.